Anzeige
Mehr »
Donnerstag, 05.06.2025 - Börsentäglich über 12.000 News
Kupfer wird knapp! Jetzt mischen sich Medien ein - und ein Explorer liefert die Story zur Fantasie
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EQWL | ISIN: US60458C1045 | Ticker-Symbol: K6S
Frankfurt
05.06.25 | 09:59
1,180 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
MIRA PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
MIRA PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,2001,26012:02

Aktuelle News zur MIRA PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
28.05.MIRA Pharmaceuticals to Participate in BIO 2025 in Boston and Highlights Ongoing Progress Across Clinical Program212The company will engage in BIO One-on-One Partnering meetings as it advances Phase 1 for Ketamir-2, prepares Phase IIa study in neuropathic pain, and finalizes filings for SKNY acquisition. MIAMI, FL...
► Artikel lesen
28.05.MIRA Pharmaceuticals gibt klinische Fortschritte und Akquisitionsupdate bekannt4
21.05.MIRA PHARMACEUTICALS, INC. - 8-K, Current Report1
14.05.MIRA PHARMACEUTICALS, INC. - 10-Q, Quarterly Report8
MIRA PHARMACEUTICALS Aktie jetzt für 0€ handeln
08.05.MIRA Pharmaceuticals board approves SKNY Pharmaceuticals acquisition; combined value tops $60M8
08.05.MIRA Pharmaceuticals erwirbt SKNY in strategischem Schritt4
08.05.MIRA Pharmaceuticals to acquire SKNY in strategic move3
08.05.MIRA Pharmaceuticals Announces Board Approval of SKNY Acquisition Reflecting $60+ Million in Combined Enterprise Value Based on Independent Review470With valuations confirmed by the board, MIRA advances strategic acquisition targeting obesity and nicotine dependence, which includes a $5 million contribution in cash or assets from SKNY to be transferred...
► Artikel lesen
08.05.EXCLUSIVE: Mira Pharmaceuticals Board Approves SKNY Pharma Acquisition, Establishing Combined Enterprise Value Over $60 Million5
06.05.MIRA Pharmaceuticals berichtet über sicheres Profil für Ketamir-29
06.05.MIRA Pharmaceuticals Reports No Brain Toxicity in FDA-Required Study of Ketamir-2, Confirming Absence of Ketamine-Linked Neurotoxicity110Preclinical data supports the advancement of oral Ketamir-2 as a safe, next-generation alternative to ketamine, with ongoing momentum in Phase I clinical trial enrollment MIAMI, FL / ACCESS Newswire...
► Artikel lesen
06.05.MIRA PHARMACEUTICALS, INC. - 8-K, Current Report4
06.05.EXCLUSIVE: MIRA Pharmaceuticals Lead Program Ketamir-2 Shows No Brain Toxicity In FDA-Mandated Study4
23.04.MIRA Pharmaceuticals reports positive in vitro drug release data for topical Ketamir-21
23.04.MIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pain Relief Market and Exploring FDA Fast Track Designation150MIAMI, FLORIDA / ACCESS Newswire / April 23, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), or MIRA, a clinical-stage pharmaceutical company focused on developing novel therapeutics for neurologic...
► Artikel lesen
23.04.MIRA PHARMACEUTICALS, INC. - 8-K, Current Report5
16.04.MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion154Ketamir-2 Demonstrates Strong Efficacy in Diabetic Neuropathy Model, with Some Subjects Achieving Complete Symptom Reversal MIAMI, FLORIDA / ACCESS Newswire / April 16, 2025 / MIRA Pharmaceuticals,...
► Artikel lesen
16.04.EXCLUSIVE: MIRA Pharmaceuticals Ketamir-2 Shows Efficacy In Diabetes-Associated Nerve Damage In Animal Study4
15.04.MIRA PHARMACEUTICALS, INC. - 10-K/A, Annual Report1
11.04.MIRA PHARMACEUTICALS, INC. - 8-K, Current Report3
Seite:  Weiter >>
57 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1